Firms grant HIV drug rights to generics makers; FDA cracks down on Luvox brochure;

 @FiercePharma: Eisai to cut Aricept costs with move to India. Article  | Follow @FiercePharma

> Three of the world's largest drug companies agreed to offer generics makers royalty-free rights to all their existing and experimental HIV medicines for sale at low cost in developing countries, in a snub to a United Nations-backed rival "patent pool." Report

> The FDA demanded that Jazz Pharmaceuticals stop distributing a patient brochure for Luvox CR and run corrective messages to counter inflated benefit claims and omission of risk information. News

> Biosimilars may have cleared their biggest stretch of wilderness thanks to their inclusion in the healthcare-reform bill, but they may run into another speedbump: payers. Article

> An FDA advisory panel will meet this week to vote on a new risk-reduction strategy for long-acting opioid-based painkillers, the use--and misuse--of which have exploded in recent years. Item

> Amylin Pharmaceuticals posted a narrower net loss on Wednesday helped by lower expenses despite weaker sales from the Byetta diabetes drug it sells with Eli Lilly. Report

> Baxter International reported a lower quarterly profit as costs rose and revenue in its bioscience unit fell. Story

> Dr. Reddy's Laboratories, India's second-biggest drugmaker, posted a 14 percent drop in first-quarter profit on weaker revenue from North America and Europe. News

> Glenmark Pharmaceuticals won the FDA nod for its version of Duramed Research's contraceptive drug Aygestin. Report

> Swiss drugs industry supplier Lonza said its business was set to recover further as clients from the pharmaceuticals industry placed more orders. Article

Biotech News

 @FierceBiotech: Shionogi, GSK move HIV drug into PhIII. News | Follow @FierceBiotech

> Radiation treatment drug granted fast track status. Item

> FDA asks NicOx for new naproxcinod trial. News

> Euthymics lands $24 million to fund antidepressant work. Article

> NuPathe plans to raise $75 million with IPO. Story

> Tibotec unveils results of experimental HIV drug. Report

Vaccines News

> HPV shot provides sustained protection against pre-cancerous growths. Item

> Funds once earmarked for HIV lab go to research. Story

Manufacturing News

> Clerics rule on vaccine containing pig material. Story

> Pfizer, Rowan pursue solvent recovery. News

> Plant building, expansions show growing global business. Article

> Research suspended at Columbia lab over GMP violations. Report

And Finally... People with high levels of the so-called good cholesterol HDL tend to have fewer heart attacks, but HDL may offer little protective benefit in people who take statins to lower harmful LDL cholesterol, U.S. researchers say. Report

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.